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ABSTRACT
Umbilical cord blood (UCB) transplantation is limited by the low number of hematopoietic stem cells in UCB
units, which results in a low engraftment rate in transplant recipients. Here, we measured the total nucleated
cell count and CD34, CD3, CD4, CD8, CD14, and CD16/56 cell doses in each UCB unit and
evaluated their influence on engraftment and other outcomes in 146 recipients. Multivariate analysis showed
a significant association between a higher incidence of successful engraftment and a dose of CD34 and CD8
cells above the median (1.4  105 and 15.7  105 cells/kg, respectively). Engraftment occurred 4 days earlier
in patients who received UCB with more than the median dose of CD34 cells than those receiving UCB at
or below the median. Stratification of the group according to CD34 cell dose revealed a significant influence
of the CD8 cell dose on the time to achieve neutrophil engraftment in patients receiving a lower CD34 cell
dose, whereas there was no significant influence in the patients receiving a higher CD34 cell dose. These
results suggest that consideration of CD34 and CD8 cell doses in UCB units may improve the engraftment
in recipients of UCB transplantation.
© 2007 American Society for Blood and Marrow Transplantation
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Umbilical cord blood (UCB) from unrelated do-
ors has been established as an alternative source for
ematopoietic stem cell (HSC) transplantation in pa-
ients who lack a human leukocyte antigen (HLA)-
atched bone marrow or a peripheral blood stem cell
PBSC) donor [1-10]. UCB transplantation (UCBT)
s limited, however, by the low number of HSCs per
nit of UCB, resulting in a low engraftment rate and
low hematopoietic recovery after transplantation. c
22here is a consensus that higher total nucleated cell
ount (TNCC) per recipient body weight and fewer
ifferences in HLAs between the donor and recipient
romote engraftment in recipients of UCBT [3,11-
4]. A higher dose of CD34 cells in UCB is also
hought to be associated with better engraftment,
ower treatment-related mortality (TRM), and higher
urvival rate in the recipients [13].
The contribution of accessory cells, which are
ryopreserved along with HSCs in UCB units, to
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CD34 and CD8 Cell Doses and Engraftment after UCBT 823ngraftment in UCBT recipients has not been well
nvestigated. In bone marrow transplantation (BMT),
t is well known that the numbers of donor T cells as
ell as HSCs can affect the engraftment rate. In hu-
ans, when compared with unmanipulated grafts, T
ell-depleted bone marrow prevents severe acute
raft-versus-host disease (aGVHD), but results in a
ower probability of engraftment [15-17]. A phase I-II
linical trial of HLA-mismatched bone marrow trans-
lantation demonstrated that the removal of CD8
ells but not CD4 cells from donor marrow increases
he risk of rejection [18]. Also, in a transplant model,
n which mice were lethally irradiated and subse-
uently reconstituted with a mixture of T cell-de-
leted syngeneic bone marrow cells and untreated
ajor histocompatibility complex (MHC)-mis-
atched allogeneic bone marrow cells, all mice devel-
ped complete chimera of the MHC-mismatched do-
or mice [19]. Another MHC-mismatched mouse
ransplant model showed that donor CD8 T cells are
t least 5-fold more effective than donor CD4T cells
or preventing marrow graft rejection [20]. Thus,
D8 T cells in the graft facilitate optimal engraft-
ent of HSCs in BMT.
In this study, we prospectively measured the
NCC and CD34, CD3, CD4, CD8, CD14,
D16/CD56 cell doses in each UCB unit shipped
rom a single cord blood registry, and we evaluated
ow these accessory cell doses affect the engraftment
nd other outcomes in 146 recipients of UCBT. The
nalyses demonstrated that a higher incidence of suc-
essful engraftment was associated with a dose of
D34 and CD8 cells above the median (1.4  105
nd 15.7  105/kg of recipient body weight, respec-
ively). Stratiﬁcation of the group according to
D34 cell dose revealed a signiﬁcant inﬂuence of the
D8 cell dose on the time to achieve neutrophil
ngraftment in the patients receiving less than the
edian dose of CD34 cells, but there was no signif-
cant inﬂuence in the patients receiving more than the
edian dose of CD34 cells. These ﬁndings and pre-
ious data [12] suggest the number of CD34 cells in
he UCB units affects the engraftment in recipients.
dditionally, the CD8 cell dose may have a beneﬁ-
ial effect on engraftment in recipients of UCBT.
ATIENTS, MATERIALS, AND METHODS
atients
Between September 1997 and August 2005, a total
f 240 UCB units were shipped from the Tokai Cord
lood Bank to transplant institutions. A total of 146
atient and UCB graft pairs were selected according
o the following criteria: (1) patients had acute leuke-
ia, other malignancies, severe aplastic anemia, severe
ombined immunodeﬁciency syndrome, or a heredi- cary metabolic disorder; (2) at least 2 agents were used
s a preconditioning regimen; (3) at least 1 immuno-
uppressant agent other than antithymocyte globulin
as used for GVHD prophylaxis; (4) an unmanipu-
ated single UCB graft was transplanted; (5) test vials
ere available for ﬂow cytometry analysis; and
6) clinical outcome data were available.
The characteristics of the patients are summarized
n Table 1. One hundred thirty-seven patients
93.8%) were treated for malignant diseases and 100
68.5%) were classiﬁed as having advanced diseases,
ncluding acute lymphoblastic leukemia (ALL) beyond
rst relapse (n  26), acute myelogenous leukemia
AML) beyond ﬁrst relapse (n  29), acute type adult
cell lymphoma/leukemia (n  7), chronic myelog-
nous leukemia (CML) in accelerated or blast phase
n  6), myelodysplastic syndrome (MDS) with excess
last (n  8), non-Hodgkin’s lymphoma refractory or
eyond second remission (n  14), and multiple my-
loma (n  3), solid tumor (n  2), or other malignan-
ies (n  5) not in complete remission (CR). The pre-
onditioning regimen varied according to disease or
tage of disease at transplantation. Thirty-seven patients
25.3%) received a regimen including ﬂudarabine with
educed total body irradiation (TBI) (10 Gy) or with-
ut TBI, which was deﬁned as a ﬂudarabine-based re-
uced intensity conditioning (RIC) regimen. As a pro-
hylaxis for GVHD, 95 patients (65.1%) received a
yclosporine A-based regimen, 44 (30.0%) received a
acrolimus-based regimen, and 84 (57.5%) received
hort-term methotrexate with or without other immu-
osuppressive agents. One hundred forty (95.9%) pa-
ients received granulocyte colony-stimulating factor
G-CSF) after transplantation.
LA Typing and Donor Matching
Conﬁrmatory HLA typing and matching of
LA-A, -B, and -DRB1 of the selected UCB unit and
ecipient were performed at the Tokai Cord Blood
ank prior to transplantation. HLA-A and -B were
yped using the standard serologic method, and HLA-
RB1 type was determined by polymerase chain re-
ction sequencing-based typing. The HLA differences
etween the patients and the UCB units are summa-
ized in Table 1.
low Cytometry of UCB Units
Flow cytometry was performed for the cells in
CB test vials when they were thawed for conﬁrma-
ory HLA typing. The doses of each cell type from the
CB units actually used for transplantation were es-
imated by multiplying the TNCC measured before
ryopreservation by the percentage of each cell frac-
ion. For immunophenotyping, cells were incubated
or 20 minutes at 4°C with 1 of the following mono-
lonal antibodies: ﬂuorescein isothiocyanate-conju-
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S. Terakura et al.824ated mouse anti-CD34, -CD3, -CD4, or -CD45 (BD
iosciences, Mountain View, CA), or phycoerythrin-
onjugated mouse anti-CD8, -CD14, -CD16, or
CD56 (BD Biosciences). The numbers of each cell
ere calculated as the percentage with a low side-
catter and using the CD45 lymphocyte gate, ad-
usted for live cells by 7-amino actinomycin D vital
ye exclusion. Counting of CD34 cells was per-
ormed according to the International Society of He-
atotherapy and Graft Engineering guidelines [21].
D3, CD4, CD8, CD14, and CD16/CD56
ell numbers were determined using a protocol based
n the guidelines from the Centers for Disease Con-
rol and Prevention [22]. Stained samples were ana-
yzed on a FACScan ﬂow cytometer (BD Biosciences)
s described perviously [23]. Approval of the study was
btained from the institutional review board of Mie
niversity Hospital.
tudy Definitions
The primary study endpoints were the engraft-
ent rate and its kinetics. The secondary study end-
oints were GVHD, TRM, relapse-free survival, and
verall survival (OS). Hematologic recovery was de-
ned as the time in days to an absolute neutrophil
ount 500/L (ﬁrst of 3 consecutive days) and a
latelet count 20,000/L (without transfusion sup-
ort). Failure of engraftment was deﬁned as the absence
f an absolute neutrophil count recovery at day 100.
atients who survived at least 14 days after transplanta-
ion were evaluated for aGVHD, and patients who sur-
ived at least 100 days after transplantation were evalu-
ted for chronic GVHD (cGVHD). aGVHD and
GVHD were graded according to standard criteria
24,25]. TRM was deﬁned as any death that occurred
hile the patient was in remission. Relapse-free survival
as deﬁned as the number of days from transplantation
o disease progression or death from any causes other
han disease progression. OS was deﬁned as the number
f days from transplantation to death from any cause.
tatistical Analysis
Prospective collection of patient characteristics
nd outcomes were performed by the Tokai Cord
lood BankDataManagement Center. Variables related
o the patients, diseases, grafts, and transplant procedure
ere compared among the groups by chi-square analysis
or categoric variables and the Mann-Whitney test for
ontinuous variables. The Kaplan-Meier method was
sed to obtain estimates of relapse-free survival and OS,
nd the log-rank test was used to evaluate differences
etween patient group strata [26]. Cumulative incidence
urves for hematopoietic recovery, GVHD, TRM, and
elapse were used, taking account of competing risks. To
alculate the probability of neutrophil and platelet re-able 1. Patient and Transplant Characteristics
Patient Characteristics n  146
ge, median, years (range) 15.0 (0.2-74.0)
ody weight, median, kg (range) 41.0 (4.8-85.0)
ecipient sex, n (%)
Male 89 (61.0)
Female 57 (39.0)
iagnosis, n (%)
Malignant disease
Acute lymphoblastic leukemia 49 (33.5)
Acute myelogenous leukemia 39 (26.7)
Adult T cell lymphoma/leukemia 8 (5.5)
Chronic myelogenous leukemia 6 (4.1)
Myelodysplastic syndrome 11 (7.5)
Non-Hodgkin’s lymphoma 14 (9.6)
Multiple myeloma 3 (2.1)
Solid tumor 2 (1.4)
Other malignancies 5 (3.4)
Nonmalignant disease
Severe aplastic anemia 3 (2.1)
Severe combined immunodeficiency
syndrome 2 (1.4)
Other nonmalignancies 4 (2.7)
isease states at transplant, n (%)
Standard 46 (31.5)
Advanced 100 (68.5)
egree of HLA match in rejection vector,
n (%)
6/6 antigens 35 (24.0)
5/6 antigens 65 (44.5)
4/6 antigens 45 (30.8)
3/6 antigens 1 (0.7)
egree of HLA match in GVH vector, n (%)
6/6 antigens 34 (23.3)
5/6 antigens 72 (49.3)
4/6 antigens 38 (26.0)
3/6 antigens 2 (1.4)
BO blood type match, n (%)
Match 48 (32.9)
Minor mismatch 42 (28.8)
Major mismatch 56 (38.3)
onditioning agents, n (%)*
Two 51 (34.9)
Three 95 (65.1)
otal body irradiation dose, n (%)
Full (>10 Gy) 75 (51.4)
Reduced (<10 Gy) 33 (22.6)
No 38 (26.0)
VHD prophylaxis, n (%)
Cyclosporine A alone 30 (20.6)
Cyclosporine A  short-term
methotrexate 55 (37.7)
Cyclosporine A  prednisolone 10 (6.8)
Tacrolimus alone 12 (8.2)
Tacrolimus  short-term methotrexate 28 (19.2)
Tacrolimus  predonisolone 4 (2.7)
Short-term methotrexate alone 1 (0.7)
Others 6 (4.1)
-CSF administration after transplantation,
n (%)
Yes 140 (95.9)
No 6 (4.1)
-CSF indicates granulocyte colony-stimulating factor.overy and GVHD, death was the competing event; for
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CD34 and CD8 Cell Doses and Engraftment after UCBT 825RM, relapse was the competing event; for relapse,
RM was the competing event [27]. Cox-proportional
azards univariate and multivariate regression models
ere applied to identify predictors of study endpoints
28]. All variables with P  .10 were entered into the
ultivariate logistic regression using a backward, step-
ise method. Day 100 posttransplant was applied as a
andmark for analysis of cGVHD as a correlate of study
ndpoints. P-values of .05 were regarded as indicating
tatistical signiﬁcance, and those between .05 and .20 as
uggesting a trend. Statistical analyses were performed
sing STATA version 8.2 software (STATACorp., Col-
ege Station, TX).
ESULTS
CB Graft Composition
We found that the TNCC, CD34, CD3,
D4, CD8, CD14, and CD16/CD56 cell
oses in the individual UCB units varied greatly (Fig-
re 1). The median TNCC was 3.2  107/kg (range:
.1-30.4  107/kg), and UCB containing 3.2 
07/kg of TNCC was used in 61 (81.3%) of 75 child
atients (15 years old) and 12 (16.9%) of 71 adult
atients (15 years old). UCB containing 2.5 
07/kg of TNCC, which is regarded as a minimum
ose for successful engraftment [9] was used in 70
93.3%) of 75 child patients and 27 (38.0%) of 71
dult patients. The median number of CD34 cells
igure 1. UCB graft cell dose. Box plot for cell doses of each cell
raction. The horizontal bar within each box plot indicates the
edian of the contained cell number. The top and bottom of the
ox indicates the 25th and 75th percentiles, respectively. The top
nd bottom of the whisker indicates the 5th and 95th percentiles,tespectively.as 1.4  105/kg (range: 0.4-8.2  105/kg), and UCB
ontaining 1.4  105/kg of CD34 cell was used in
3 (70.7%) of 75 child patients and 18 (25.4%) of 71
dult patients. UCB containing 1.7  105/kg of
D34 cells, which has been proposed by Wagner et
l. [13] as the minimum for engraftment, was used in
2 (56.0%) of 75 child patients and 8 (11.3%) of 71
dult patients. The median numbers and ranges of
D3, CD4, CD8, CD14, and CD16/CD56
ells are summarized in Figure 1.
ngraftment and Hematopoietic
ecovery Kinetics
The cumulative incidence of engraftment at day
0 was 0.81 (95% conﬁdence interval [CI], 0.74-0.87).
total of 26 patients (17.8%) did not exhibit an
ngraftment. Of these patients, 15 died on or before
ay 28 and 3 died after day 28 from neutropenia.
hree patients died of early progression of their dis-
ase, and the remaining 5 patients were censored on
he day of the second transplantation because of pri-
ary engraftment failure. For the 120 patients who
xhibited engraftment, the median time to achieve
eutrophil engraftment was 22 days (range: 12-49
ays), and the median time to achieve platelet engraft-
ent was 44 days (range: 12-135 days).
Univariate analysis of engraftment revealed a sig-
iﬁcant association with a higher incidence of engraft-
ent failure with higher patient age and body weight
s a continuous variable and with a median or lower
NCC and CD34, CD3, CD4, CD8, and
D16/CD56 dose (Table 2). A trend for a higher
ncidence of engraftment failure (P-value between
.05 and 0.20) was found in the patients with advanced
isease, an HLA mismatch in the rejection vector in
or more loci, and a ﬂudarabine-based reduced in-
ensity conditioning (RIC) regimen. Multivariate
nalysis showed a signiﬁcant association between a
igher incidence of engraftment failure and a lower
ose of CD34 cells (1.4  105/kg) and CD8 cells
15.7  105/kg).
The time to achieve neutrophil engraftment in the
atients receiving more than a median dose of CD34
ells (median: 21 days; range: 12-49 days) was signif-
cantly earlier than that in patients receiving a median
r lower dose of CD34 cells (25 days; 12-48 days)
P  .0001 at day 21 and P  .0001 at day 28). The
verall incidences of engraftment in each patient
roup were 90.4% and 72.3% (P .004), respectively.
We next evaluated the inﬂuence of the CD8 cell
ose on the cumulative incidence of neutrophil en-
raftment in each patient group according to CD34
ell dose (Figure 2). In the group receiving more than
he median dose of CD34 cells, the time to achieve
eutrophil engraftment was similar (median: 21 days;
ange: 12-49 days) in the patients receiving more than
he median dose of CD8 cells (15.7  105/kg) than
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S. Terakura et al.826n those receiving this dose or less (median: 22 days;
ange: 15-43 days; P .11 on day 21); however, in the
roup receiving less than the median dose of CD34
ells, the time to achieve neutrophil engraftment was
igniﬁcantly earlier in the patients receiving more
han the median dose of CD8 cells (median: 21 days;
ange: 17-33 days) than in those receiving less than the
edian dose (median: 25 days; range: 12-48 days) (P
0047 at day 21).
Finally, no signiﬁcant factor was identiﬁed by ei-
her univariate or multivariate analysis for platelet
ecovery.
VHD
Of 130 patients that could be evaluated, aGVHD
as scored as grade 0 (n  36; 27.7%), I (n  41;
1.5%), II (n  37; 28.5%), III (n  10; 7.7%), or IV
n  6; 4.6%). The cumulative incidences of grades
I-IV and III-IV aGVHD were 0.41 (95% CI, 0.32-
.50) and 0.14 (95% CI, 0.08-0.22), respectively. Cox
egression analysis showed a signiﬁcant association
etween a higher incidence for grade II-IV aGVHD
nd an HLA mismatch in the graft-versus-host
able 2. Univariate and Multivariate Analyses for Engraftment
Significant Factor
Hazard Ratio
(95% CI)*** P-value
nivariate analysis
Background
Age* 1.01 (1.00-1.02) .007
Body weight* 1.01 (1.00-1.02) .001
Advanced disease 1.34 (0.91-1.98) .14
HLA mismatch (one or more)** 1.47 (0.97-2.17) .067
Conditioning
Two conditioning agents 1.24 (0.85-1.82) .26
Fludarabine-based RIC regimen 1.46 (0.92-2.30) .10
Total body irradiation dose* 1.00 (0.97-1.03) .97
Immunosuppression
Tacrolimus (vs. cyclosporine) 0.93 (0.63-1.38) .73
The use of methotrexate 0.84 (0.58-1.22) .37
G-CSF administration
Yes 0.76 (0.31-1.87) .55
Graft cell dose
TNCC >3.2  107/kg 0.60 (0.41-0.87) .006
CD34 >1.4  105/kg 0.46 (0.31-0.66) <.0001
CD3 >31.2  105/kg 0.63 (0.44-0.91) .015
CD4 >23.8  105/kg 0.59 (0.41-0.86) .005
CD8 >15.7  105/kg 0.50 (0.34-0.72) .0002
CD14 >14.0  105/kg 1.21 (0.84-1.75) .31
CD16/CD56 >16.0  105/kg 0.64 (0.45-0.92) .017
Multivariate analysis
CD34 dose >1.4  105/kg 0.56 (0.37-0.85) .007
CD8 dose >15.7  105/kg 0.65 (0.43-0.99) .047
IC indicates reduced intensity conditioning; G-CSF, granulocyte
colony-stimulating factor.
Continuous variable.
*HLA mismatch in rejection vector.
**A hazard ratio over 1.00 indicates that the category is a risk factor
for an engraftment failure.GVH) vector in 1 or more loci and a higher CD8 tell dose (15.7  105/kg) (Table 3). A trend for a
igher incidence of grades III-IV aGVHD was found
n the patients who received15.7 105/kg of CD8
ells (hazard ratio: 2.15; 95% CI, 0.78-5.96; P  .14).
igure 2. Cumulative incidence of engraftment. A, Cumulative
ncidence of engraftment in the patients who received more than
edian dose of CD34 cells (1.4  105/kg). The solid line
ndicates the patients receiving more than the median dose of CD8
ells (15.7  105/kg), and the dotted line indicates the patients
eceiving a median or lower dose of CD8 cells (15.7  105/kg).
he overall incidences of engraftment in each patient group were
.93 (n  53) and 0.85 (n  20), respectively. B, Cumulative
ncidence of engraftment in the patients who received a median or
ower dose of CD34 cells (1.4 105/kg). The solid line indicates
he patients receiving more than the median dose of CD8 cells,
nd the dotted line indicates the patients receiving a median or
ower dose of CD8 cells. The overall incidences of engraftment in
ach patient group were 0.90 (n  20) and 0.66 (n  53), respec-
ively.
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CD34 and CD8 Cell Doses and Engraftment after UCBT 827Of 116 patients that could be evaluated, the cu-
ulative incidence of cGVHD was 0.16 (95% CI,
.10-0.23). Cox regression analysis showed a trend for
higher incidence of cGVHD in the patients who
eceived UCBT from an HLA mismatched donor in
he GVH vector in 1 or more loci (hazard ratio: 3.23;
5% CI, 0.93-11.1; P  .065). There was no signiﬁ-
ant association between each cell dose and the inci-
ence of cGVHD.
elapse
Relapse was observed in 41 of 137 patients treated
or malignant disease (median: day 110; range: day
-655). The cumulative incidence of relapse at 2 years
as 0.31 (95% CI, 0.24-0.40) for all patients with ma-
ignant disease, 0.31 (0.18-0.45) for patients with ALL
n  49), and 0.33 (0.19-0.49) for patients with AML
n 39). Cox regression analysis revealed a signiﬁcant
ssociation between advanced disease at transplanta-
ion and a higher incidence of relapse (Table 3). There
as no signiﬁcant association between each cell dose
nd the incidence of relapse.
reatment-Related Mortality
The cumulative incidences of TRM at day 100 and
65 were 0.25 (95% CI, 0.18-0.32) and 0.35 (0.28-
.43), respectively. Cox regression analysis showed a
igniﬁcant association between a higher TRM and an
LA mismatch in the GVH vector in 1 or more loci,
udarabine-based RIC regimen, and not using short-
erm methotrexate (Table 3). There was no signiﬁcant
able 3. Multivariate Analyses for GVHD, Relapse, Treatment-
elated Mortality, Relapse-Free Survival, and Overall Survival
Outcome and Significant Factor
Hazard Ratio
(95% CI) P-value
rade II-IV acute GVHD
HLA mismatch (one or more)* 2.70 (1.25-5.88) .012
CD8 >15.7  105/kg 2.02 (1.16-3.55) .014
elapse
Advanced disease 2.71 (1.25-5.88) .012
reatment-related mortality
HLA mismatch (one or more)* 8.33 (2.13-33.3) .003
Fludarabine-based RIC regimen 2.29 (1.24-4.23) .008
Use of short-term methotrexate 0.50 (0.27-0.93) .027
elapse-free survival
Advanced disease 1.73 (1.05-2.83) .031
HLA mismatch (one or more)* 2.08 (1.19-3.70) .010
Use of short-term methotrexate 0.55 (0.36-0.83) .005
verall survival
HLA mismatch (one or more)* 2.63 (1.39-4.76) .003
Fludarabine-based RIC regimen 1.81 (1.09-3.00) .021
Use of short-term methotrexate 0.52 (0.32-0.83) .006
VHD indicates graft-versus-host disease; RIC, reduced intensity
conditioning.
HLA mismatch in GVH vector.ssociation between each cell dose and TRM. telapse-Free Survival and Overall Survival
The cumulative incidences of relapse-free survival
nd OS at 3 years after transplantation were 0.33
95% CI, 0.24-0.41) and 0.37 (0.28-0.46), respec-
ively. The median follow-up time for surviving pa-
ients was 24 months (range: 2-62). Cox regression
nalysis revealed a signiﬁcant association between a
ower relapse-free survival rate with advanced disease,
n HLA mismatch in the GVH vector in 1 or more
oci, and not using short-term methotrexate (Table 3).
here was also a signiﬁcant association between a
ower OS and an HLA mismatch in the GVH vector
n 1 or more loci, a ﬂudarabine-based RIC regimen,
nd not using short-term methotrexate (Table 3).
here was no signiﬁcant association between each cell
ose and relapse-free survival or OS.
ISCUSSION
In UCBT, engraftment in the recipients is an
mportant surrogate marker because of there is a lower
ngraftment rate and a delayed blood recovery com-
ared to bone marrow or PBSC transplantation [6,7].
e analyzed the inﬂuence of CD34 and other ac-
essory cell doses in UCB grafts on the engraftment
ate and kinetics in recipients, and we demonstrated
hat a higher CD34 cell dose is associated with suc-
essful engraftment. In patients receiving more than
.4  105/kg of CD34 cells, the engraftment oc-
urred 4 days earlier than in patients receiving 1.4 
05/kg or less CD34 cells. Wagner et al. [13] also
eported that the CD34 cell dose is associated with
ngraftment in recipients of UCBT. They showed
hat the rate and probability of engraftment were
arkedly lower in patients receiving 1.7  105/kg of
D34 cells compared with those receiving a higher
ose of these cells. These ﬁndings suggest that the
D34 cell dose in UCB grafts is a deﬁnitive predic-
or of the engraftment rate and kinetics after UCBT
nd that the threshold dose for assured and rapid
ngraftment is approximately 1.4-1.7  105/kg, al-
hough differences in methodologies for measuring
D34 cells could inﬂuence the exact threshold dose.
A few studies have attempted to show an inﬂuence
f the CD34 cell dose on engraftment after UCBT,
ut most of them have not been able to conﬁrm that
here is an effect [11,29]. These studies have deter-
ined the CD34 cell dose using different techniques
nd institutions [11] or in small populations (30
atients) [29]. In contrast, Wagner et al. [13] esti-
ated the infused CD34 cell dose by ﬂow cytometry
f an aliquot of the infused UCB cells under a ﬁxed
ondition at a single institution and in a larger study
opulation (n  102). We also estimated the cell dose
y measuring the percentage of CD34 cells in UCB
est vials at a single institution, although there is no
a
u
i
C
b
s
T
r
t
g
C
c
t
t
m
p
.
t
.
i
H
f
B
C
r
m
T
K
p
e
m
r
o
r
a
g
o
o
S
a
h
t
C
o
T
s
U
b
n
m
w
r
t
b
t
r
T
d
r
s
g
c
T
C
U
a
s
c
p
u
o
e
[
a
v
m
m
m
w
u
T
f
t
h
m
u
i
d
p
o
s
p
p
s
e
e
p
p
p
b
o
r
r
H
S. Terakura et al.828ssurance that the compositions of the test vial and the
nit actually thawed and infused into the patients were
dentical. It is well known that the measurement of
D34 cells cannot be used for comparative studies
etween transplant centers because of the absence of
tandard thawing, sampling, and counting methods.
he use of a standardized technique with sufﬁcient
eproducibility is essential for accurately evaluating
he association between cell components in the UCB
raft and their role in UCBT.
We showed for the ﬁrst time that a higher dose of
D8 cells (15.7  105/kg) in UCB grafts is asso-
iated with successful engraftment. Stratiﬁcation of
he group according to CD34 cell dose revealed that
here is a signiﬁcant inﬂuence of CD8 cells on the
edian time to achieve neutrophil engraftment in the
atients receiving lower CD34 cell doses (P 
0047), whereas there was no signiﬁcant inﬂuence in
he patients receiving a higher CD34 cell dose (P 
11). These results suggest CD8 cells have a support-
ve role in the engraftment of UCB containing fewer
SCs.
The mechanism of action by which CD8 T cells
acilitate engraftment has been extensively studied in
MT [30]. Earlier studies demonstrated that donor
D8 T cells eliminate residual immune cells of the
ecipient via perforin or a Fas ligand-dependent
echanism [20,31]. Several subpopulations of CD8
cells have been reported to facilitate engraftment.
aufman et al. [32] reported that CD8 T cells ex-
ressing T cell receptor (TCR)-associated CD3 mol-
cules but not TCRs can facilitate marrow engraft-
ent without causing GVHD. Gandy et al. [33] later
eported that TCRT cells also facilitate engraftment
f highly enriched HSCs in allogeneic recipients. It
emains possible that other mechanisms such as “veto
ctivity” as deﬁned by Miller [34] contribute to the
raft-enhancing effect. Veto cells can induce apoptosis
f cytotoxic T cells that are directed against antigens
f the veto cells via a Fas-Fas ligand interaction [35].
ome of the most potent veto cells are of T cell origin,
nd in particular, CD8 cytotoxic T lymphocytes
ave a very high veto activity [36,37]. We showed here
hat each UCB unit contains a considerable number of
D8 cells (median, 15.7  105/kg), which is 1 to 2
rders of magnitude more than cells obtained from
cell-depleted bone marrow by CD34 positive
election (typically 105 CD8 cells/kg). T cells in
CB are more naive than adult lymphocytes [38],
ut, as described above, expression of the TCR is
ot necessarily required for facilitation of engraft-
ent by T cells. Overall, these results are consistent
ith the idea that CD8 T cells play an important
ole in facilitating HSC engraftment in transplan-
ation of UCB. rAlthough both CD34 cells and CD8 cells had a
eneﬁcial effect on engraftment, neither cell popula-
ion affected survival in UCBT recipients. This may
esult from the heterogeneity of the study population.
he patients had a variety of diseases and severity of
isease, and they received a variety of preconditioning
egimens and prophylaxis for GVHD (Table 1). A
tudy population with a more homogenous back-
round is required to deﬁne the contribution of these
ell populations on survival after transplantation.
hus, our results do not exclude the possibility that
D34 and/or CD8 cell doses inﬂuence survival in
CBT recipients.
Interestingly, the use of methotrexate was associ-
ted with lower rates of TRM and higher relapse-free
urvival and OS (Table 3). Although it was not asso-
iated with lower incidence of aGVHD in this study
opulation (Table 2), we previously demonstrated that
se of methotrexate has a signiﬁcant favorable effect
n post-UCBT immune reactions and OS in a differ-
nt study population [39]. In contrast, Locatelli et al.
40] reported that the use of methotrexate is unfavor-
ble for neutrophil engraftment and event-free sur-
ival in a study of 44 pediatric patients with thalasse-
ia and sickle cell disease. Accordingly, the effect of
ethotrexate on UCBT outcome remains unclear. It
ight be worth further investigation to determine
hether there is an explanation for the ﬁnding that the
se of methotrexate is associated with a lower risk of
RM and higher rate of survival.
A ﬂudarabine-based RIC regimen was a risk factor
or TRM. Because we used registry data in this study,
he patients who were at high risk for TRM might
ave tended to receive an RIC regimen rather than a
yeloablative regimen. In addition, the RIC regimens
sed in this study greatly varied. Thus, another study
s required to determine whether the RIC regimen
ecreases TRM and improves the survival rate in the
atients who are at high risk for TRM.
We studied the effect of the dose of CD34 and
ther cells on engraftment in patients receiving a
ingle unmanipulated UCB graft and an immunosup-
ressant other than ATG. Antithymocyte globulin as a
reconditioning or posttransplantation immunosuppres-
ive treatment would considerably attenuate the inﬂu-
nce of T cells, but the role of natural killer cells could be
xpected to become more important [41,42]. Thus, the
resent results should be interpreted with caution for
atients treated with ATG or other T cell depletion
rocedures.
In summary, the present study demonstrated that
oth CD34 and CD8 cells have a beneﬁcial effect
n engraftment in UCBT recipients, and our ﬁndings
aise the possibility that CD8 cells have a supportive
ole in engraftment of UCB units containing fewer
SCs. Further analysis in a larger population is war-anted. If our ﬁndings are conﬁrmed, if all of the UCB
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CD34 and CD8 Cell Doses and Engraftment after UCBT 829nits accompany their test vial, and if the measure-
ents of CD34 and CD8 cells are standardized, it
ay be worthwhile to consider the doses of both
D34 and CD8 cells as well as TNCC and HLA
atching for UCB graft selection strategies.
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